SGLT2 inhibitor use was also associated with a lower risk of mortality (HR 0.61; 95% CI 0.39–0.94; P = 0.025) and CV mortality (HR 0.43; 95% CI 0.21–0.86; P = 0.018), but not of MI (HR 1.22 [95% CI 0.72–2.09]; P = 0.461) or stroke (HR 1.00 [95% CI 0.75–1.33]; P = 0.980). The gene discussed is SLC5A2; the disease is Stroke.